Hisike Signs $87M Collaboration Agreement with Eli Lilly on May 29

According to Hisike's announcement, Hisike Pharma Tech (Lhasa), a wholly-owned subsidiary of Hisike, and Eli Lilly signed an authorization and research collaboration agreement on May 29, 2026. The two parties will jointly develop and conduct early-stage research on up to five novel drug targets across multiple disease areas, with Hisike eligible to receive an initial payment of up to $87 million from Eli Lilly.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments